miRview Test for Mesothelioma
Page Edited by Patient Advocate Dave Foster This page has been fact checked by an experienced mesothelioma Patient Advocate. Sources of information are listed at the bottom of the article.
We make every attempt to keep our information accurate and up-to-date.
Free Mesothelioma Packet
- New treatment options
- Learn from survivors
- Veterans benefits & claims
- File for your share of $30 billion in trust funds
Please Contact Us with any questions or comments.
Diagnosing mesothelioma is complicated, but new technologies are making it easier and more accurate. Legal teams currently use the miRview test for mesothelioma, made by Rosetta Genomics, to prove or disprove a patient has mesothelioma caused by asbestos exposure. The test may prove useful in helping all patients get more timely, accurate diagnoses.
The Difficulty of Diagnosing Mesothelioma
Mesothelioma is difficult to diagnose for a number of reasons. A patient may go to the doctor for symptoms that mimic many less serious conditions or even other types of lung cancer. Because mesothelioma is rare, it is not often considered a possible diagnosis until other conditions have been ruled out.
Free Mesothelioma Packet
- New treatment options
- Learn from survivors
- Veterans benefits & claims
- File for your share of $30 billion in trust funds
Even using diagnostic techniques to image the chest and lungs can be faulty. Finding abnormal tissue or fluid in the lungs or pleura is not indicative of mesothelioma. Biopsies used to examine suspicious cells under a microscope can also be misinterpreted. It is difficult to distinguish between cancer cells that came from the mesothelium and those that came from other parts of the body.
The miRview Meso Test
One of the difficulties in diagnosing mesothelioma is distinguishing it from other cancers. Even when tests show a patient has cancer in or around the lungs, determining whether that cancer started in the mesothelium or is one of several subtypes of lung cancer is not easy. Rosetta Genomics developed a biomarker test that can make that process easier and more accurate.
The miRview test uses microRNA biomarkers, molecules that indicate the presence of a certain disease, to accurately determine the origin of cancer cells in the body.[1] The test is relatively new, but it has shown it can identify the likely primary origin of cancer cells. The miRview meso test is specific to mesothelioma and can distinguish between cancer cells caused by mesothelioma and those caused by a type of lung cancer.[2]
The sensitivity of the test has been found to be 100%, while the specificity is 94%; better accuracy than any other test for mesothelioma. The test only requires that a doctor perform a biopsy to get a sample of tissue. Usually a needle biopsy is sufficient. The sample can then be tested with the miRview meso test to get results.
Legal Implications
The miRview meso test is fairly new. It has so far largely been used in legal cases in which former employees are suing their employer over asbestos exposure that may have caused mesothelioma. These cases have been complicated by the fact that it is so difficult to distinguish between mesothelioma caused by asbestos exposure and lung cancer from other causes. If a simple test can confirm or deny asbestos-caused mesothelioma, it can result in fairer outcomes for lawsuits.
Rosetta Genomics
The miRview tests, including miRview meso, were developed by a company called Rosetta Genomics. It has focused on microRNA technology, using biomarkers first discovered in the 1990s. It took years to discover that they can be used as biomarkers for disease. Rosetta has so far discovered hundreds of unique segments of microRNA that can be used to diagnose a number of different types of cancer.
The potential for Rosetta’s tests to provide more accurate and earlier cancer diagnoses is enormous. For people with aggressive and difficult cancers like mesothelioma, this test could literally be a life saver. More research is needed before miRview becomes a regular test for mesothelioma. Current clinical trials, for instance, are examining whether this test is cost-effective as compared to traditional diagnostic techniques.
Page Edited by Patient Advocate Dave Foster
Dave has been a mesothelioma Patient Advocate for over 10 years. He consistently attends all major national and international mesothelioma meetings. In doing so, he is able to stay on top of the latest treatments, clinical trials, and research results. He also personally meets with mesothelioma patients and their families and connects them with the best medical specialists and legal representatives available.